Allergy immunotherapy: Reduced health care costs in adults and children with allergic rhinitis

Hankin, Cheryl S.; Cox, Linda; Bronstone, Amy; Wang, Zhaohui

doi:10.1016/j.jaci.2012.12.662

Cited by 81 publications

(43 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This will not only improve quality of life of the patient and lessen the direct and indirect costs related to the disease but also will be economical to the health care system. 22,23 …”

Section: Discussionmentioning

confidence: 99%

Non-adherence to subcutaneous allergen immunotherapy: inadequate health insurance coverage is the leading cause

Vaswani

Garg

Parikh

et al. 2015

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

“…This will not only improve quality of life of the patient and lessen the direct and indirect costs related to the disease but also will be economical to the health care system. 22,23 …”

Section: Discussionmentioning

confidence: 99%

Non-adherence to subcutaneous allergen immunotherapy: inadequate health insurance coverage is the leading cause

Vaswani

Garg

Parikh

et al. 2015

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

“…201 Retrospective and prospective observational studies have shown that SCIT and SLIT positively affect healthcare expenditure in pharmacotherapy with a reduction in expenditure of 12% to 80%. [202][203][204][205][206] A reduction in medical costs in the AIT vs placebo groups has been repeatedly reported, but these savings did not compensate the costs of AIT. 202,207,208 In contrast to cost-only studies, cost-effectiveness and cost-utility analysis evaluate the effects of treatment in terms of clinical benefits or health-related quality of life (i.e, quality-adjusted life years [QALYs]).…”

Section: Pharmacoeconomic Aspe Cts Of Ait Versus Pharmacothe Rapy Fmentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

593

705

View full text Add to dashboard Cite

drawn on data from a systematic review of the literature, more recent published studies and multistakeholder expert clinical opinion. This Guideline is aimed at healthcare professionals who are encouraged to take the recommendations into account in the context of delivering clinical care. This Guideline is not a substitute for professional clinical judgment, which professionals need to exercise in the context of delivering personalised healthcare. AbstractAllergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project "EAACI Guidelines on Allergen Immunotherapy." It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach.The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass 766 | ROBERTS, PFAAR ET AL. tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children. | ME TH ODOLOGYThis Guideline was produced using the Appraisal of Guidelines forResearch & Evaluation (AGREE II) approach, 17,18 a structured approach to guideline production (see Table S1). This is designed to ensure appropriate representation of the full range of stakeholders, a careful search for and critical appraisal of the relevant literature, a systematic approach to the formulation and presentation of recommendations and steps to ensure that the risk of bias is minimized at each step of the process. The process started on April 2015 beginning with detailed face-to-face discussions agreeing on the process and the key clinical areas to address, followed by face-to-face meetings, and regular web conferences in which professional and lay representatives participated. | Clarifying the scope and purpose of the guidelinesThe scope of this EAACI Guideline is multifaceted...

show abstract

“…22 En otras investigaciones se ha observado que después de un año de tratamiento, los pacientes presentan un mejor control de los síntomas, lo que permite reducir con pocas recaídas la farmacoterapia hasta en 30 a 45%. [23][24][25][26] En forma similar a nuestra investigación, esos estudios indican que aun cuando en los primeros meses el costo del tratamiento para asma o rinitis aumenta por la inmunoterapia, a mediano plazo este costo se reduce significativamente, incluso, el costo llega a ser menor que en los pacientes que solo reciben el tratamiento farmacológico. Es importante anotar que esta reducción es secundaria al mejor control de los síntomas, lo que potencialmente implica menor número de asistencias a urgencias y hospitalizaciones, mejoría en la calidad de vida de los pacientes y menor riesgo de efectos adversos por la farmacoterapia.…”

Section: Discussionunclassified

Consecuencias económicas en la vida real de la inmunoterapia con alérgenos en asma, rinitis y dermatitis

Sánchez

2016

RAM

View full text Add to dashboard Cite

Este artículo debe citarse como: Sánchez J, Sánchez A, Cardona R. Consecuencias económicas en la vida real de la inmunoterapia con alérgenos en asma, rinitis y dermatitis. Rev Alerg Mex. 2016;63(4):323-333 Consecuencias económicas en la vida real de la inmunoterapia con alérgenos en asma, rinitis y dermatitis Correspondencia: Jorge Sánchez. jotamsc@yahoo.com Recibido: 2016-01-17 Aceptado: 2016 AbstractBackground: Allergen immunotherapy has proved effective in the treatment of various allergies, but whether the clinical benefits outweigh the economic costs has been little evaluated. Objective: To explore the economic consequences of immunotherapy in asthma, rhinitis and dermatitis. Methods: Descriptive study. Patients with at least 18 months' follow-up were selected, whose medical history allowed evaluation of drugs received, manner of use, check-ups, treatment changes, reasons for these, and so on. Patients were classified according to whether they received drug treatment + immunotherapy (active group) or drug therapy alone (control group). Results: 1848 patients were included: 648 in the active group and 1200 in the control. Immunotherapy increased the cost of treatment during the first few months, but after 9 to 12 months drug treatment decreased significantly compared to the control group. In patients with asthma or various diseases, immunotherapy reduced costs of treatment (p < 0.05). The active group saw fewer relapses at 18 months (p < 0.05). Conclusion: Allergen immunotherapy allows the sustained reduction in drug treatment, with medium-term financial savings for the patient and the health system.

show abstract

Allergy immunotherapy: Reduced health care costs in adults and children with allergic rhinitis

Cited by 81 publications

References 55 publications

Non-adherence to subcutaneous allergen immunotherapy: inadequate health insurance coverage is the leading cause

Non-adherence to subcutaneous allergen immunotherapy: inadequate health insurance coverage is the leading cause

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Consecuencias económicas en la vida real de la inmunoterapia con alérgenos en asma, rinitis y dermatitis

Contact Info

Product

Resources

About